Old Web
English
Sign In
Acemap
>
authorDetail
>
Tianyi Liu
Tianyi Liu
AstraZeneca
Medicine
Budesonide
Cost-effectiveness analysis
Exacerbation
COPD
4
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cost-effectiveness analysis of COPD screening programs in primary care for high-risk patients in China.
2021
npj Primary Care Respiratory Medicine
Shuli Qu
Xuedan You
Tianyi Liu
Lijiao Wang
Zheng Yin
Yanjun Liu
Chong-ye
Ting Yang
Mao Huang
Hongchao Li
Liwen Fang
Jinping Zheng
Show All
Source
Cite
Save
Citations (1)
Cost-effectiveness analysis of double low-dose budesonide and low-dose budesonide plus montelukast among pediatric patients with persistent asthma receiving Step 3 treatment in China.
2020
Journal of Medical Economics
Xiaoling Wang
Honghao Fang
Kunling Shen
Tianyi Liu
Jipan Xie
Yuantao Liu
Peibei Wu
Yilin Chen
Jia Zhong
Eric Q. Wu
Wei Zhou
Bin Wu
Show All
Source
Cite
Save
Citations (1)
The cost-effectiveness of low-dose budesonide as a Step 2 treatment for pediatric asthma in China.
2020
Journal of Comparative Effectiveness Research
Xiaoling Wang
Honghao Fang
Kunling Shen
Tianyi Liu
Jipan Xie
Yuantao Liu
Jia Zhong
Eric Q. Wu
Wei Zhou
Bin Wu
Show All
Source
Cite
Save
Citations (0)
Comparative analysis of medical expenditure with nebulized budesonide versus systemic corticosteroids in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease in China
2019
International Journal of Chronic Obstructive Pulmonary Disease
Jing Zhang
Wanzhen Yao
Xuedan You
Tianyi Liu
Yuantao Liu
Show All
Source
Cite
Save
Citations (2)
1